Format

Send to

Choose Destination
Int J Mol Sci. 2019 Nov 23;20(23). pii: E5875. doi: 10.3390/ijms20235875.

The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases.

Author information

1
Department of Experimental Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
2
Department of Women, Child, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.

Abstract

Endocannabinoid system consists of cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, their endogenous ligands, and the enzymes responsible for their synthesis and degradation. CB2, to a great extent, and CB1, to a lesser extent, are involved in regulating the immune response. They also regulate the inflammatory processes by inhibiting pro-inflammatory mediator release and immune cell proliferation. This review provides an overview on the role of the endocannabinoid system with a major focus on cannabinoid receptors in the pathogenesis and onset of inflammatory and autoimmune pediatric diseases, such as immune thrombocytopenia, juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease, obesity, neuroinflammatory diseases, and type 1 diabetes mellitus. These disorders have a high social impact and represent a burden for the healthcare system, hence the importance of individuating more innovative and effective treatments. The endocannabinoid system could address this need, representing a possible new diagnostic marker and therapeutic target.

KEYWORDS:

CB1 receptor; CB2 receptor; endocannabinoid system; immune regulation; inflammation

PMID:
31771129
DOI:
10.3390/ijms20235875
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center